Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1624884 | 0.94 | LMNA (0.42) | LMNAPOLBKMT2AMEN1CYP1A2 | |
| SCHEMBL6130762 | 0.84 | KMT2A (0.44) | LMNAPOLBKMT2AMEN1GAA | |
| SCHEMBL103605 | 0.81 | GAA (0.44) | LMNAPOLBCYP1A2GAAATAD2 | |
| Acetic Acid Methyl Ester SCHEMBL28329738 | 0.81 | POLB (0.52) | LMNAPOLBKMT2AGAAATAD2 | |
| SCHEMBL6647291 | 0.77 | POLB (0.50) | LMNAPOLBGAAATAD2TP53 | |
| Acetic Acid SCHEMBL27871291 | 0.77 | POLB (0.51) | LMNAPOLBCYP1A2GAAATAD2 | |
| Thymine SCHEMBL6686289 | 0.76 | ATAD2 (0.58) | LMNAPOLBGAAATAD2TP53 | |
| SCHEMBL104485 | 0.75 | KMT2A (0.51) | LMNAKMT2AGAAATAD2MAPT | |
| SCHEMBL28628364 | 0.74 | LMNA (0.39) | LMNAKMT2AGAAATAD2 | |
| SCHEMBL1162321 | 0.74 | POLB (0.46) | LMNAPOLBKMT2ACYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4858 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| US-12577554-B2 | Methods for purification of messenger RNA | TRANSLATE BIO, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | TRANSLATE BIO, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-12552858-B2 | Methods and compositions for delivering mRNA coded antibodies | TRANSLATE BIO, INC. (US) | 2026-02-17 | — | — | US | claimed |
| EP-4659246-A1 | ELECTROCHEMICAL SYNTHESIS WITH REDOX STABLE NUCLEOTIDES | Atlas Data Storage, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250368986-A1 | ELECTROCHEMICAL SYNTHESIS WITH REDOX STABLE NUCLEOTIDES | ATLAS DATA STORAGE INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250257360-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | UNIV OKLAHOMA (US) | 2025-08-14 | — | — | US | claimed |
| WO-2025137576-A1 | MULTIPLE SPECIFIC ANTIBODIES TARGETING CD19, CD20, AND/OR CD47 | NUTCRACKER THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4504945-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | The Board of Regents of the University of Oklahoma (US) | 2025-02-12 | — | — | EP | claimed |
| US-12146139-B2 | Oligonucleotide interference treatments of prostate cancer | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2024-11-19 | — | — | US | claimed |
| US-20130195867-A1 | RNA-CODED ANTIBODY | CUREVAC GMBH (DE) | 2013-08-01 | — | — | US | claimed |
| WO-2012138530-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-10-11 | — | — | WO | claimed |
| US-7807356-B2 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | claimed |
| US-20100189729-A1 | RNA-CODED ANTIBODY | CURVAC GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| EP-2101823-A2 | RNA-CODED ANTIBODY | Curevac GmbH (DE) | 2009-09-23 | — | — | EP | claimed |
| US-7524942-B2 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. (US) | 2009-04-28 | — | — | US | claimed |
| WO-2008083949-A2 | RNA-CODED ANTIBODY | CUREVAC GMBH (DE) | 2008-07-17 | — | — | WO | claimed |
| US-20080124708-A1 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. | 2008-05-29 | — | — | US | claimed |
| US-20070212697-A1 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. | 2007-09-13 | — | — | US | claimed |
| US-5998596-A | Inhibition of protein kinase activity by aptameric action of oligonucleotides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-07 | — | — | US | claimed |